首页 > 抗体蛋白 > 抗体
APC/Cyanine7 anti-mouse CD4 Antibody
产品名称:
APC/Cyanine7 anti-mouse CD4 Antibody
产品类别:
抗体
产品编号:
100525
产品应用:
100525
[价格]
规格 价格 库存
25µg ¥ 1232 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF? Purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Additional Product Notes
BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Jarick KJ, et al. 2018. Front Immunol. 9:1468. PubMed
  2. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  3. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
  4. Ma F, et al. 2020. Cell Death Dis. 1.172222222. PubMed
  5. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
  6. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  7. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  8. Pokrovskii M, et al. 2020. EMBO J. 39:e104159. PubMed
  9. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  10. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  11. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  12. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  13. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  14. Guo HF, et al. 2021. Commun Biol. 4:482. PubMed
  15. Wei M, et al. 2014. Protein Eng Des Sel. 27:289. PubMed
  16. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  17. Shiomi A, et al. 2014. J Immunol. 193:849. PubMed
  18. Cuburu N, et al. 2019. J Immunol. 202:1250. PubMed
  19. Westfall S, et al. 2020. Brain Behav Immun. . PubMed
  20. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  21. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  22. Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed
  23. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  24. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  25. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  26. Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed
  27. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  28. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  29. Tan X, et al. 2021. Sci Adv. 7: . PubMed
  30. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  31. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
  32. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
  33. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  34. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  35. Saigusa R, et al. 2018. Arthritis Res Ther. 20:23. PubMed
  36. Boehm DT, et al. 2019. NPJ Vaccines. 4:40. PubMed
  37. Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  38. Dionisio-Santos DA, et al. 2021. Front Neurosci. 15:758677. PubMed
  39. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
  40. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  41. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  42. Brennd?rfer E, et al. 2014. J Immunol. 192:1671. PubMed
  43. Yokomizo-Nakano T, et al. 2020. Cancer Res. 80:2523. PubMed
  44. Yun H, et al. 2020. Immunity. 53(5):1050-1062.e5. PubMed
  45. Ulrich V, et al. 2016. EMBO Mol Med. 8: 643 - 653. PubMed
  46. Weng Q, et al. 2018. Cell Regen (Lond). 7:7. PubMed
  47. Koide S, et al. 2022. iScience. 25:103603. PubMed
  48. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  49. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  50. Aryal B, et al. 2016. Nat Commun. 7:12313. PubMed
  51. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  52. Kumar R, et al. 2020. Cell Reports. 30(8):2512-2525. PubMed
  53. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  54. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  55. Howie D, et al. 2019. Front Immunol. 10:1860. PubMed
  56. Cobbold SP, et al. 2018. Front Immunol. 9:1381. PubMed
  57. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
RRID
AB_312726 (BioLegend Cat. No. 100525) AB_312727 (BioLegend Cat. No. 100526)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线